Secondary analysis of a phase 3 placebo-controlled brilaroxazine trial (406 participants with acute psychosis): a speech latency ratio identified 228 vocal-biomarker-positive patients, in whom brilaroxazine beat placebo on nearly every outcome measure.
Secondary analysisn = 406
Cohen et al. A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials